Schering AG starts phase 2 trials of epothilone, ZK-EPO, in breast, ovarian cancer

By Lisa Kerner

Erie, Pa., May 23 - Schering AG said it began two new phase 2 proof-of-concept clinical studies in the United States and Canada evaluating its novel epothilone, ZK-EPO, for the treatment of metastatic breast cancer and recurrent ovarian cancer.

In the single arm, open-label phase 2 metastatic breast cancer trial, ZK-EPO will be administered every three weeks to patients who had up to three previous lines of taxane and anthracycline chemotherapy. The second phase 1/2 trial with ZK-EPO in combination with carboplatin will enroll patients with recurrent ovarian cancer after first-line treatment with platinum-based chemotherapy, according to a company news release.

Schering said two additional studies will be conducted in North America, possibly in the second half of this year.

ZK-EPO is currently being evaluated for non-small-cell lung, small-cell lung, breast and ovarian cancers in phase 2 trials in Europe

A phase l study in patients with various solid tumors is ongoing in Japan, the company said.

Schering AG is a research-based pharmaceutical company located in Berlin, Germany.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.